We are live on ! Find out more
COLL icon

Collegium Pharmaceutical
COLL

124 hedge funds and large institutions have $492M invested in Collegium Pharmaceutical in 2018 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 47 increasing their positions, 35 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

546% more call options, than puts

Call options by funds: $6.12M | Put options by funds: $948K

34% more repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 35

6.66% more ownership

Funds ownership: 94.08% → 100.74% (+6.7%)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

7% less funds holding

Funds holding: 133 → 124 (-9)

29% less first-time investments, than exits

New positions opened: 20 | Existing positions closed: 28

33% less capital invested

Capital invested by funds: $739M → $492M (-$247M)

Holders
124
Holders Change
-9
Holders Change %
-6.77%
% of All Funds
2.83%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
20
Increased
47
Reduced
35
Closed
28
Calls
$6.12M
Puts
$948K
Net Calls
+$5.17M
Net Calls Change
+$6.36M

Top Buyers

Rank Fund Capital Flow
1
JGC
J. Goldman & Co
New York
+$23.1M
2
SAM
Sectoral Asset Management
Quebec, Canada
+$15.5M
3
Franklin Resources
Franklin Resources
California
+$6.15M
4
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$5.49M
5
Massachusetts Financial Services
Massachusetts Financial Services
Massachusetts
+$4.08M

Top Sellers

Rank Fund Capital Flow
1
CM
Castleark Management
Illinois
-$6.99M
2
SPPAM
Summit Partners Public Asset Management
Massachusetts
-$6.97M
3
OCM
Osterweis Capital Management
California
-$5.43M
4
NIP
Nicholas Investment Partners
California
-$5M
5
Millennium Management
Millennium Management
New York
-$4M
Name Holding Trade Value Shares
Change 		Change in
Stake
Two Sigma Investments
26
Two Sigma Investments
New York
$3.37M +$3.8M +214,116 +1,508%
Charles Schwab
27
Charles Schwab
California
$3.05M +$913K +51,489 +33%
SSA
28
Schonfeld Strategic Advisors
New York
$3.03M +$3.65M +205,800 New
USAA
29
United Services Automobile Association
Texas
$2.99M +$1.24M +70,160 +53%
LPL Financial
30
LPL Financial
California
$2.96M +$152K +8,558 +4%
Bank of New York Mellon
31
Bank of New York Mellon
New York
$2.91M -$724K -40,857 -17%
GIM
32
Granahan Investment Management
Massachusetts
$2.9M +$1.23M +69,577 +55%
Citadel Advisors
33
Citadel Advisors
Florida
$2.81M +$3.02M +170,197 +828%
Millennium Management
34
Millennium Management
New York
$2M -$4M -225,571 -62%
PPA
35
Parametric Portfolio Associates
Washington
$1.32M +$423K +23,854 +36%
Deutsche Bank
36
Deutsche Bank
Germany
$1.14M -$1.86M -104,686 -57%
TCIM
37
TIAA CREF Investment Management
New York
$1.14M -$128K -7,211 -9%
TA
38
Teachers Advisors
New York
$1.14M +$79.5K +4,484 +6%
GCP
39
GSA Capital Partners
United Kingdom
$1.13M +$590K +33,300 +76%
EMG
40
ETF Managers Group
New Jersey
$898K +$104K +5,848 +11%
Citigroup
41
Citigroup
New York
$813K +$928K +52,338 +1,866%
Squarepoint
42
Squarepoint
New York
$765K +$321K +18,100 +54%
SO
43
STRS Ohio
Ohio
$748K +$307K +17,300 +52%
Wells Fargo
44
Wells Fargo
California
$739K +$580K +32,706 +188%
California State Teachers Retirement System (CalSTRS)
45
California State Teachers Retirement System (CalSTRS)
California
$662K -$53 -3 -0%
T. Rowe Price Associates
46
T. Rowe Price Associates
Maryland
$623K +$749K +42,262 New
NC
47
NBW Capital
Massachusetts
$562K -$25.6K -1,446 -4%
Swiss National Bank
48
Swiss National Bank
Switzerland
$560K – – –
AllianceBernstein
49
AllianceBernstein
Tennessee
$548K – – –
ARTA
50
A.R.T. Advisors
New York
$530K -$936K -52,814 -59%
1
2
3 4 5

COLL Hedge Fund Activity: Q3 2018 in Review

124 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Collegium Pharmaceutical (COLL) for Q3 2018, worth a combined $492M — down 33% from $739M a quarter earlier.

Sellers outnumbered buyers: 28 funds closed out of COLL and 20 opened new positions — a net loss of 8 holders — while 35 trimmed existing stakes and 47 added.

The largest buyer was J. Goldman & Co, adding an estimated $23.1M. The largest seller was Castleark Management, exiting entirely with an estimated $6.99M sold.

  • 124 institutional investors held Collegium Pharmaceutical (COLL) as of Q3 2018, down from 133 in Q2 2018.
  • Funds reported $492M of Collegium Pharmaceutical stock for Q3 2018, down 33% quarter-over-quarter.
  • 20 funds opened new Collegium Pharmaceutical positions in Q3 2018 and 28 closed out, a net change of -8 holders.
  • The largest Collegium Pharmaceutical buyer in Q3 2018 was J. Goldman & Co, an estimated $23.1M added.
  • The largest Collegium Pharmaceutical seller in Q3 2018 was Castleark Management, an estimated $6.99M sold.

Based on aggregated 13F filings for Q3 2018.